文献速递肝病

贝扎贝特治疗UDCA难治性原发性胆汁性胆管炎的5年配对肝活检纵向研究

Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
PubMed 文献 · Aliment Pharmacol Ther · 2021-09-29

49例可分析,31例完成5年活检;ALP、AST、ALT、GGT显著改善,12个月时86%患者ALP恢复正常;Ludwig与Ishak评分显著下降,48%患者纤维化消退,肝硬化比例从19%降至3%。

要点

  • UDCA联合贝扎贝特可显著改善UDCA难治性PBC患者的生化指标。
  • 5年配对肝活检显示Ludwig和Ishak评分显著下降,48%患者纤维化消退。
  • 肝硬化比例从基线19%降至5年时3%,GLOBE和UK-PBC预后评分改善。

核心结论

  • UDCA难治性PBC患者加用贝扎贝特5年后纤维化和炎症组织学评分显著下降。

主要发现

  • 49例可分析,31例完成5年配对肝活检;血清ALP、AST、ALT和GGT显著改善。
  • 12个月时86%患者ALP达到正常水平。
  • Ludwig评分从基线2.29±1.2降至5年1.84±1(P=0.0242),Ishak评分从6.19±2.2降至4.77±2.2(P=0.0008)。
  • 48%患者纤维化消退,肝硬化比例从基线19%降至5年3%(P<0.001)。
  • GLOBE和UK-PBC预后模型预测风险评分改善。

临床怎么用

  • 对UDCA应答不完全的PBC患者,可考虑加用贝扎贝特以改善生化和组织学结局。

局限性

  • 样本量有限,仅31例完成5年配对肝活检。
  • 作者指出获益需进一步在长期队列研究和对照试验中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ursodeoxycholic acid (UDCA) is the first-line therapy for primary biliary cholangitis (PBC). However, nearly 40% of patients have an incomplete response to UDCA. The addition of bezafibrate has shown biochemical benefit in this group of patients. AIM: To evaluate the long-term effects of UDCA in combination with bezafibrate on histological outcomes in patients with UDCA-refractory PBC. METHODS: Fifty-nine patients refractory to UDCA were included. Clinical parameters were monitored and paired liver biopsy (PLB) was performed after 5 years of follow-up. RESULTS: Of the total cohort, 49 subjects were analysed and 31 had PLB at 5 years. Values for serum ALP, AST, ALT and GGT significantly improved with UDCA-bezafibrate. This beneficial effect was observed at 12 months where 86% achieved ALP at normal levels. Analyses of PLB showed a significant decrease in liver damage as reflected by Ludwig (baseline 2.29 ± 1.2, to 1.84 ± 1 at year 5, P = 0.0242) and Ishak (baseline 6.19 ± 2.2 to 4.77 ± 2.2 at year 5, P = 0.0008) scores. Overall, regression of fibrosis was attained in 48% of patients. Furthermore, we observed a significant reduction in the proportion with cirrhosis from 19% at baseline to 3% at 5 years (P < 0.001). These beneficial effects were associated with better predictive risk scores using the GLOBE and UK-PBC prognosis models. CONCLUSIONS: Adding bezafibrate to UDCA in patients with UDCA-refractory PBC showed a significant decrease in fibrosis and inflammatory histological scores at 5 years. These beneficial effects warrant further evaluation in long-term cohort studies and controlled trials.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sorda JA, González Ballerga E, Barreyro FJ, et al. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. Aliment Pharmacol Ther. 2021. PMID: 34587309. doi:10.1111/apt.16618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。